Search Results

Collaboration is the catalyst—let’s redefine what’s possible in GPCR-driven therapeutics.   

So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic

tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic

Here’s what Premium Members accessed this week  across four critical domains: Industry insights:  Neurocrine

unique allosteric signal transmission mechanisms between the Nb80-binding site and the extracellular domains

His work highlights how foundational GPCR science can drive therapeutic innovation.

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK

tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics

Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces once dominated by small molecules.

of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics

leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics

activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics

and technologies, as well as target validation strategies for the discovery and development of novel therapeutic

Carlsson’s takeaway: AlphaFold is a powerful starting point, but domain expertise and experimental grounding

how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve as more responsive therapeutic

FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics

As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently

activity without directly competing with ligands, potentially reducing side effects and increasing therapeutic the findings of this study have significant implications for drug design, personalised medicine, and therapeutic

and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics

Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic

Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics

cardiometabolic disease, and gain insights into novel approaches in neurodegeneration and antibody therapeutics missed by traditional screening methods, gaining a first-mover advantage in developing more effective therapeutics

his interview, Regulators of G protein Signaling (RGS proteins)  might hold some of the most untapped therapeutic

As a result, cryo-EM has begun to make major impacts in bringing critical therapeutics to market. In this review, we discuss recent instructive examples of impacts from cryo-EM in therapeutics design

Pina Cardarelli, CSO of GPCR Therapeutics.

Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics

the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic

Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic